In a study presented by Hadoux et al at the European Society for Medical Oncology (ESMO) Congress 2023, investigators compared selpercatinib as first-line therapy with either cabozantinib or vandetanib (control group) in patients with advanced thyroid cancer (Abstract LBA3).
